Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Arcus Biosciences, Inc. Common Stock (NY:RCUS)

23.12 +0.41 (+1.81%)
Official Closing Price Updated: 1:10 PM EST, Dec 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Arcus Biosciences, Inc. Common Stock

< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
News headline image
Arcus Surges As Executive Transfer Could Signal Deeper Gilead Partnership ↗
An Arcus executive jumped ship for a role at Gilead, but RCUS stock popped Tuesday on expectations for a closer relationship. 
Via Investor's Business Daily
News headline image
Arcus Biosciences Announces New Employment Inducement Grants
From Arcus Biosciences
Via Business Wire
News headline image
Why Arcus Biosciences' Big Reveal Wasn't Very Exciting ↗
No news from Arcus Biosciences is bad news for the company and other industry heavyweights. 
Via The Motley Fool
News headline image
45 Biggest Movers From Yesterday ↗
Gainers Marin Software Incorporated (NASDAQ: MRIN) shares surged 105.3% to close at $3.51 on Thursday after the company announced it has added the ability to manage Instacart Ads... 
Via Benzinga
News headline image
Arcus Biosciences Announces New Employment Inducement Grants
From Arcus Biosciences
Via Business Wire
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
Gainers Pieris Pharmaceuticals (NASDAQ:PIRS) stock moved upwards by 27.11% to $4.5 during Thursday's regular session. As of 12:30 EST, this security is trading at a... 
Via Benzinga
News headline image
36 Stocks Moving In Thursday's Mid-Day Session ↗
Gainers Marin Software Incorporated (NASDAQ: MRIN) jumped 58% to $2.70 after the company announced it has added the ability to manage Instacart Ads to its flagship MarinOne... 
Via Benzinga
News headline image
Here's Why Arcus Biosciences Stock Is Rising Today ↗
Investors expecting Gilead Sciences to license Arcus Biosciences' lead asset could be in for an unpleasant surprise. 
Via The Motley Fool
News headline image
Arcus Biosciences Rockets, But Vague Update In Cancer Study Divides Analysts ↗
Arcus Biosciences offered a vague update on its lung cancer regimens Wednesday, but RCUS stock rocketed on Thursday. 
Via Investor's Business Daily
News headline image
Mid-Morning Market Update: Markets Open Higher; Accenture Reports Upbeat Q3 Results ↗
Following the market opening Thursday, the Dow traded up 0.76% to 34,130.38 while the NASDAQ rose 0.75% to 14,379.10. The S&P also rose, gaining 0.54% to 4,264.62. The U.S.... 
Via Benzinga
Topics Stocks
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
Gainers Aravive (NASDAQ:ARAV) stock moved upwards by 21.61% to $6.47 during Thursday's pre-market session. The company's market cap stands at $131.9 million. Arcus... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Lilly Spikes On Alzheimer's Drug Regulatory Filing Plan, Applied Genetics, Arcus Issue Data Readouts, Adcom Test Awaits Incyte, Monte Rosa Prices IPO ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 23) AngioDynamics, Inc. (NASDAQ... 
Via Benzinga
News headline image
10 Biggest Price Target Changes For Thursday ↗
Goldman Sachs boosted Lear Corporation (NYSE:LEA) pr... 
Via Benzinga
News headline image
25 Stocks Moving in Thursday's Pre-Market Session ↗
Gainers Marin Software Incorporated (NASDAQ: MRIN) rose 43.3% to $2.45 in pre-market trading after the company announced it has added the ability to manage Instacart Ads to its... 
Via Benzinga
News headline image
7 Stocks Moving In Wednesday's After-Hours Session ↗
Gainers Applied Genetic Technologies (NASDAQ: AGTC) shares are trading higher after the company announced that it plans to release 12-month data for adult patients and low-dose... 
Via Benzinga
News headline image
Anti-TIGIT Domvanalimab-Based Combinations Showed Encouraging Clinical Activity in People with Metastatic, PDL1-High Non-Small Cell Lung Cancer at First Interim Analysis of Arcus Biosciences’ Randomized Phase 2 ARC-7 Study
From Arcus Biosciences
Via Business Wire
News headline image
Arcus Biosciences Announces New Employment Inducement Grants
From Arcus Biosciences
Via Business Wire
News headline image
Arcus Biosciences Announces New Employment Inducement Grants
From Arcus Biosciences, Inc.
Via Business Wire
News headline image
Arcus Biosciences Presents Early Data from ARC-6, a Phase 1b/2 Study Evaluating Etrumadenant-Based Combinations in Metastatic Castrate-Resistant Prostate Cancer at the 2021 ASCO Annual Meeting
From Arcus Biosciences
Via Business Wire
News headline image
Arcus Biosciences Announces New Employment Inducement Grants
From Arcus Biosciences
Via Business Wire
News headline image
Arcus Biosciences Reports First Quarter 2021 Financial Results and Provides Operational Highlights
From Arcus Biosciences
Via Business Wire
News headline image
Last Week's Notable Insider Buys: Beacon Roofing, Chipotle, IPOs, Latham And More ↗
Insider buying can be an encouraging signal for potential investors, especially when markets are near all-time highs. Once again, some insiders took advantage of recent public... 
Via Benzinga
News headline image
Arcus Biosciences Announces New Employment Inducement Grants
From Arcus Biosciences, Inc.
Via Business Wire
News headline image
Arcus Biosciences Presents Updated Data for Etrumadenant in Third-Line Metastatic Colorectal Cancer and New Data on its HIF-2α Program at the AACR 2021 Annual Meeting
From Arcus Biosciences, Inc.
Via Business Wire
News headline image
Arcus Biosciences Announces New Employment Inducement Grants
From Arcus Biosciences
Via Business Wire
< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.